David Weisman MD

In 2008, Dr. Weisman founded the Clinical Research Center at Abington Neurological Associates (ANA). While serving as the site’s director, Dr. Weisman conducted and overseen numerous clinical trials: Alzheimer’s disease, stroke, multiple sclerosis, Parkinson’s disease, migraines, and chronic pain.  Dr. Weisman has become a leading trialist nationwide. Under Dr. Weisman’s direction, the ANA Clinical Trial Center has become nationally recognized.

The site participated in the first positive later stage trial in early Alzheimer’s disease, now FDA approved as Leqembi.  We randomized the first subject in the successful phase 2 trial of donanemab worldwide. ANA served as a site investigating ocrelizumab and ofatumumab in multiple sclerosis; inhaled levodopa in Parkinson’s disease; several novel migraine medications; and better stroke prevention and acute treatment.

Our mission is to partner with our subjects and discover the truth about drugs.  Subject wellbeing and trial integrity are our dual priorities.  To achieve this, we enroll medically optimized subjects, whom we hold in the highest regard, to get clear answers.  Internally we strive for a culture of accountability at every level.  Problems and errors must be accepted with compassion and solved with transparency.  Our ideals are respect, accountability, and the scientific process.